Axonal pathology in multiple sclerosis: relationship to neurologic disability.

In this review, data is summarized supporting the hypothesis that axonal loss is a major pathologic process responsible for irreversible neurologic disability in patients with multiple sclerosis. Pathologic studies implicate inflammatory demyelination as a principal cause of axonal transection and subsequent axonal degeneration. Axonal degeneration caused by chronic demyelination in the absence of active inflammation may also contribute to progressive disability in the later stages of the disease. Studies using magnetic resonance spectroscopy suggest that axonal loss begins at the onset of the disease, and studies using magnetic resonance imaging have documented brain atrophy in the earliest stages of multiple sclerosis. Brain atrophy increases during the relapsing-remitting disease stage without concurrent disability progression. This suggests that compensatory mechanisms maintain neurologic function, despite progressive brain tissue loss during the early stages of the disease. Beyond a threshold, however, further axonal loss leads to continuously progressive neurologic disability. We hypothesize that the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a patient enters the secondary progressive stage of the disease. This view of disease pathogenesis has several important implications. First, surrogate markers of axonal loss are needed to monitor the disease process for patient care and for clinical trials. We propose brain parenchymal fraction, a precise measure of whole-brain atrophy, as an attractive candidate for this purpose. Second, disease-modifying therapy should be used early in multiple sclerosis patients, before extensive axonal loss has occurred. Third, neuroprotective drugs should be tested in combination with anti-inflammatory drugs in multiple sclerosis patients. Finally, studies of the time course of axonal loss, and its mechanisms are critical for effective therapeutic intervention.

[1]  G. Wolswijk Chronic Stage Multiple Sclerosis Lesions Contain a Relatively Quiescent Population of Oligodendrocyte Precursor Cells , 1998, The Journal of Neuroscience.

[2]  Virginia M. Y. Lee,et al.  Myelin-Associated Glycoprotein Is a Myelin Signal that Modulates the Caliber of Myelinated Axons , 1998, The Journal of Neuroscience.

[3]  H. Bruhn,et al.  Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.

[4]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[5]  J. Benjamins,et al.  Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[6]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[7]  P. Leigh,et al.  A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.

[8]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[9]  S. Snyder,et al.  Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A , 1997, Nature Medicine.

[10]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Rudick,et al.  Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .

[12]  B. Gold,et al.  The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  T. J. Putnam STUDIES IN MULTIPLE SCLEROSIS: VII. SIMILARITIES BETWEEN SOME FORMS OF ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS , 1936 .

[14]  J H Simon,et al.  Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. , 1987, AJNR. American journal of neuroradiology.

[15]  W. Mcdonald RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.

[16]  L. Scheinberg,et al.  Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[17]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[18]  W. Bradley Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies , 1987, Muscle & nerve.

[19]  M. Raff,et al.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium , 1983, Nature.

[20]  J. Goldman,et al.  Endogenous Progenitors Remyelinate Demyelinated Axons in the Adult CNS , 1997, Neuron.

[21]  B. Gold,et al.  The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. , 1994, Restorative neurology and neuroscience.

[22]  K. Lloyd CNS compensation to dopamine neuron loss in Parkinson's disease. , 1977, Advances in experimental medicine and biology.

[23]  J. Levine,et al.  Development and differentiation of glial precursor cells in the rat cerebellum , 1993, Glia.

[24]  I. Duncan,et al.  Repair of myelin disease: strategies and progress in animal models. , 1997, Molecular medicine today.

[25]  G. Parry,et al.  A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis , 1996 .

[26]  L. S. King,et al.  OBSERVATIONS ON THE HISTOPATHOLOGY OF THE CEREBRAL LESIONS IN DISSEMINATED SCLEROSIS , 1936 .

[27]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[28]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[29]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[30]  V. Tuohy,et al.  Normal and reactive NG2+ glial cells are distinct from resting and activated microglia , 1997, Journal of neuroscience research.

[31]  M. Gaweł,et al.  Effect of recombinant human insulin-like growth factor-I on progression of ALS , 1997, Neurology.

[32]  D. Price,et al.  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. B. George,et al.  Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Brück,et al.  Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions , 1998, Multiple sclerosis.

[35]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[36]  Jia Newcombe,et al.  High Resolution Proton NMR Spectroscopy of Multiple Sclerosis Lesions , 1995, Journal of neurochemistry.

[37]  C. Heldin,et al.  Co‐localization of NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells in the developing rat brain , 1996, Journal of neuroscience research.

[38]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[39]  M. Noble,et al.  Identification of an adult-specific glial progenitor cell. , 1989, Development.